Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to -$18.3 million.

  • Perspective Therapeutics' Free Cash Flow rose 3060.31% to -$18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.7 million, marking a year-over-year decrease of 16295.68%. This contributed to the annual value of -$72.7 million for FY2024, which is 9141.24% down from last year.
  • As of Q3 2025, Perspective Therapeutics' Free Cash Flow stood at -$18.3 million, which was up 3060.31% from -$21.0 million recorded in Q2 2025.
  • Perspective Therapeutics' Free Cash Flow's 5-year high stood at $4.8 million during Q1 2024, with a 5-year trough of -$41.2 million in Q4 2024.
  • Moreover, its 5-year median value for Free Cash Flow was -$8.9 million (2023), whereas its average is -$10.6 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 43743.9% in 2021, then crashed by 64937.19% in 2025.
  • Perspective Therapeutics' Free Cash Flow (Quarter) stood at $2.8 million in 2021, then crashed by 325.41% to -$6.2 million in 2022, then plummeted by 45.86% to -$9.1 million in 2023, then crashed by 353.12% to -$41.2 million in 2024, then skyrocketed by 55.64% to -$18.3 million in 2025.
  • Its Free Cash Flow was -$18.3 million in Q3 2025, compared to -$21.0 million in Q2 2025 and -$26.2 million in Q1 2025.